|Table of Contents|

Clinicopathological features and prognosis analysis of mixed invasive ductal-lobular carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2020 03
Page:
415-421
Research Field:
Publishing date:

Info

Title:
Clinicopathological features and prognosis analysis of mixed invasive ductal-lobular carcinoma
Author(s):
Chen Shujie; Ji Min; He Qi
Department of Breast Surgery，the International Peace Maternity & Child Health Hospital of China Welfare Institute，Shanghai Jiaotong University School of Medicine，Shanghai 200030，China.
Keywords:
breast cancer; mixed invasive ductal-lobular carcinoma; invasive lobular carcinoma; invasive ductal carcinoma; clinicopathological feature; prognosis
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2020.03.014
Abstract:
Objective：To investigate the differences of clinicopathological features and prognosis in mixed invasive ductal-lobular carcinoma (IDC-L)，invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC).Methods：We retrospectively analyzed the differences of clinicopathological features and prognosis between IDC-L，ILC and IDC patients which had complete clinicopathological and follow up data from Shanghai Jiaotong University Breast Cancer Database (SJTU-BCDB) between January 2009 and December 2015.Results：A total of 2 957 patients were enrolled，in which 109 were IDC-L，177 were ILC，and 2 671 were IDC.Multivariate analysis showed that compared to IDC-L，IDC patients were less likely to have multicenter lesion and lymphovascular invasion，and more likely to be HER2 positive and high expression of Ki-67 (P<0.05).Compared to IDC-L，ILC had older patients and less lymphovascular invasion (P<0.05).IDC-L patients were associated with decreased breast cancer-free interval (BCFI) and overall survival (OS) compared to IDC patients (BCFI：82.1% vs 90.7%，P=0.040，OS：91.0% vs 94.4%，P=0.029)，while IDC-L patients had similar BCFI (82.1% vs 84.1%，P=0.803) and OS (91.0% vs 92.6%，P=0.803) with ILC patients.Multivariate analysis revealed that BCFI and OS were significantly associated with pathological type，tumor size，lymph node status and molecular subtype (P<0.05).IDC-L patients had worse BCFI (HR=1.67，95%CI：1.02~2.70，P=0.042) and OS (HR=1.89，95%CI：1.04~3.45，P=0.037) than IDC patients.Conclusion：The clinicopathological features of IDC-L patients are similar to those of ILC patients，but different from IDC patients.The prognosis of IDC-L is worse than that of IDC，but has no significant difference from ILC，which needs further study.

References:

［1］Sinn HP，Kreipe H.A brief overview of the WHO classification of breast tumors，4th edition，focusing on issues and updates from the 3rd edition［J］.Breast Care (Basel)，2013，8(2)：149-154.
［2］Li CI，Uribe DJ，Daling JR.Clinical characteristics of different histologic types of breast cancer［J］.Br J Cancer，2005，93(9)：1046-1052.
［3］Dossus L，Benusiglio PR.Lobular breast cancer：Incidence and genetic and non-genetic risk factors［J］.Breast Cancer Res，2015(17)：37-44.
［4］Reynoso-Noverón N，Villarreal-Garza C，Soto-Perez-de-Celis E，et al.Clinical and epidemiological profile of breast cancer in Mexico：Results of the Seguro Popular［J］.J Glob Oncol，2017，3(6)：757-764.
［5］Flores Díaz D，Arce C，Flores Luna L，et al.Impact of invasive lobular carcinoma on long-term outcomes in Mexican breast cancer patients［J］.Breast Cancer Res，2019，176(1)：243-249.
［6］Chen Z，Yang J，Li S，et al.Invasive lobular carcinoma of the breast：A special histological type compared with invasive ductal carcinoma［J］.PLoS One，2017，12(9)：1-17.
［7］Li CI，Anderson BO，Daling JR，et al.Trends in incidence rates of invasive lobular and ductal breast carcinoma［J］.Jama，2003，289(11)：1421-1424.
［8］Lamovec J，Bracko M.Metastatic pattern of infiltrating lobular carcinoma of the breast：an autopsy study［J］.J Surg Oncol，1991，48(1)：28-33.
［9］Arpino G，Bardou VJ，Clark GM，et al.Infiltrating lobular carcinoma of the breast：tumor characteristics and clinical outcome［J］.Breast Cancer Res，2004，6(3)：R149-R156.
［10］Pestalozzi BC，Zahrieh D，Mallon E，et al.Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast：Combined results of 15 international breast cancer study group clinical trials［J］.J Clin Oncol，2008，26(18)：3006-3014.
［11］Wasif N，Maggard MA，Ko CY，et al.Invasive lobular vs.ductal breast cancer：a stage-matched comparison of outcomes［J］.Ann Surg Oncol，2010，17(7)：1862-1869.
［12］Hanagiri T，Nozoe T，Mizukami M，et al.Clinicopathological characteristics of invasive lobular carcinoma of the breast［J］.Asian J Surg，2009，32(2)：76-80.
［13］Yoder BJ，Wilkinson EJ，Massoll NA.Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast［J］.Breast J，2007，13(2)：172-179.
［14］Thomas M，Kelly ED，Abraham J，et al.Invasive lobular breast cancer：a review of pathogenesis，diagnosis，management，and future directions of early stage disease［J］.Semin Oncol，2019，46(2)：121-132.
［15］Mamtani A，King TA.Lobular breast cancer：different disease，different algorithms［J］.Surg Oncol Clin N Am，2018，27(1)：81-94.
［16］Rakha EA，Gill MS，El-Sayed ME，et al.The biological and clinical characteristics of breast carcinoma with mixed ductal and lobular morphology［J］.Breast Cancer Res，2009，114(2)：243-250.
［17］Arps DP，Healy P，Zhao L，et al.Invasive ductal carcinoma with lobular features：A comparison study to invasive ductal and invasive lobular carcinomas of the breast［J］.Breast Cancer Res，2013，138(3)：719-726.
［18］Zengel B，Yararbas U，Duran A，et al.Comparison of the clinicopathological features of invasive ductal，invasive lobular，and mixed (invasive ductal+invasive lobular) carcinoma of the breast［J］.Breast Cancer，2015，22(4)：374-381.
［19］Bharat A，Gao F，Margenthaler JA.Tumor characteristics and patient outcomes are similar between invasive lobular and mixed invasive ductal/lobular breast cancers but differ from pure invasive ductal breast cancers［J］.Am J Surg，2009，198(4)：516-519.
［20］Goldhirsch A，Winer EP，Coates AS，et al.Personalizing the treatment of women with early breast cancer：Highlights of the St gallen international expert consensus on the primary therapy of early breast cancer 2013［J］.Ann Oncol，2013，24(9)：2206-2223.
［21］Hudis CA，Barlow WE，Costantino JP，et al.Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials：The STEEP system［J］.J Clin Oncol，2007(25)：2127-2132.
［22］Suryadevara A，Paruchuri LP，Banisaeed N，et al.The clinical behavior of mixed ductal/lobular carcinoma of the breast：A clinicopathologic analysis［J］.World J Surg Oncol，2010(8)：51-59.
［23］Metzger-Filho O，Ferreira AR，Jeselsohn R，et al.Mixed invasive ductal and lobular carcinoma of the breast：Prognosis and the importance of histologic grade［J］.Oncologist，2019，24(7)：e441-e449.
［24］McCart Reed AE，Kutasovic JR，Nones K，et al.Mixed ductal-lobular carcinomas：Evidence for progression from ductal to lobular morphology［J］.J Pathol，2018，244(4)：460-468.
［25］Acs G，Lawton TJ，Rebbeck TR，et al.Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications［J］.Am J Clin Pathol，2001，115(1)：85-98.

Memo

Memo:
-
Last Update: 1900-01-01